The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
LITFULO (Pfizer Australia Pty Ltd)
Product name
LITFULO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
104 (120 working days)
Active ingredients
ritlecitinib tosylate
Registration type
NCE/NBE
Indication
LITFULO is indicated for the treatment of severe alopecia areata (AA) in adults and adolescents 12 years of age and older (see Section 5.1 Pharmacodynamic properties).